Sökning: onr:"swepub:oai:DiVA.org:liu-21256" >
Addition of inflixi...
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial) : 1-year results of a randomised trial
-
- van Vollenhoven, R.F. (författare)
- Karolinska Institutet,Karolinska University Hospital
-
- Ernestam, S. (författare)
- Karolinska Institutet,Karolinska University Hospital
-
- Geborek, Pierre (författare)
- Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Hospital
-
visa fler...
-
- Petersson, Ingemar (författare)
- Lund University,Lunds universitet,Ortopedi, Lund,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Orthopaedics (Lund),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Hospital
-
- Cöster, Lars (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Reumatologi,Hälsouniversitetet,Länskliniken för Reumatologi i Östergötland
-
- Waltbrand, E. (författare)
- Lasarettet, Borås
-
- Zickert, A. (författare)
- Karolinska Institutet,Danderyds Hospital
-
- Theander, J. (författare)
- Centralsjukhuset, Kristianstad
-
- Thorner, A. (författare)
- Mälarsjukhuset
-
- Hellstrom, H. (författare)
- Lasarettet, Falun
-
- Teleman, A. (författare)
- Spenshult Hospital
-
- Dackhammar, C. (författare)
- University Hospital, Mölndal
-
- Akre, F. (författare)
- University Hospital, Örebro
-
- Forslind, K. (författare)
- Lund University Hospital
-
- Ljung, Lotta (författare)
- Umeå universitet,Reumatologi,University Hospital, Umeå
-
- Oding, R. (författare)
- Centrallasarettet, Västerås
-
- Chatzidionysiou, A. (författare)
- Karolinska Institutet,Karolinska University Hospital
-
- Wornert, M. (författare)
- Karolinska University Hospital
-
- Bratt, J. (författare)
- Karolinska Institutet,Karolinska University Hospital
-
visa färre...
-
(creator_code:org_t)
- 2009
- 2009
- Engelska.
-
Ingår i: The Lancet. - 0140-6736 .- 1474-547X. ; 374:9688, s. 459-466
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: New treatment strategies for early rheumatoid arthritis are evolving rapidly. We aimed to compare addition of conventional disease-modifying antirheumatic drugs (sulfasalazine and hydroxychloroquine) with addition of a tumour necrosis factor antagonist (infliximab) to methotrexate in patients with early rheumatoid arthritis. Methods: We undertook a randomised trial in 15 rheumatology units in Sweden. We enrolled patients with early rheumatoid arthritis (symptom duration less than1 year) and administered methotrexate (up to 20 mg per week). After 3-4 months, those who had not achieved low disease activity but who could tolerate methotrexate were randomly allocated by computer addition of either sulfasalazine and hydroxychloroquine or infliximab. Primary outcome was achievement of a good response according to European League Against Rheumatism (EULAR) criteria at 12 months. Patients were followed up to 24 months; here, we present findings at 12 months. Analysis was by intention to treat and we used non-responder imputation. The Swefot (Swedish Pharmacotherapy) study is registered in the WHO database at the Karolinska University Hospital, number CT20080004. Findings: 487 patients were initially enrolled. Of 258 who had not achieved low disease activity with methotrexate, 130 were allocated sulfasalazine and hydroxychloroquine and 128 were assigned infliximab. 32 of 130 (25%) patients allocated sulfasalazine and hydroxychloroquine achieved the primary outcome compared with 50 of 128 (39%) assigned infliximab (risk ratio 1·59 [95% CI 1·10-2·30], p=0·0160). Adverse events were balanced fairly well between the two groups and accorded with known adverse events of the drugs used. No deaths occurred in either group. Interpretation: In patients with early rheumatoid arthritis in whom methotrexate treatment failed, addition of a tumour necrosis factor antagonist to methotrexate monotherapy is clinically superior to addition of conventional disease-modifying antirheumatic drugs. Funding: Swedish Rheumatism Association, Schering-Plough.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Ortopedi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Orthopaedics (hsv//eng)
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
van Vollenhoven, ...
-
Ernestam, S.
-
Geborek, Pierre
-
Petersson, Ingem ...
-
Cöster, Lars
-
Waltbrand, E.
-
visa fler...
-
Zickert, A.
-
Theander, J.
-
Thorner, A.
-
Hellstrom, H.
-
Teleman, A.
-
Dackhammar, C.
-
Akre, F.
-
Forslind, K.
-
Ljung, Lotta
-
Oding, R.
-
Chatzidionysiou, ...
-
Wornert, M.
-
Bratt, J.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Reumatologi och ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Ortopedi
- Artiklar i publikationen
-
The Lancet
- Av lärosätet
-
Linköpings universitet
-
Umeå universitet
-
Karolinska Institutet
-
Lunds universitet